The COVID-19 pandemic resulted in federal policy changes related to telehealth use that allowed states to maximize access to medications for opioid use disorder (MOUD) through telehealth.
Breadcrumb
- Home
- Resources and Tools
Resources and Tools
The growing opioid crisis across the United States has resulted in an increase in new HIV diagnoses.
Individuals who have HIV who also use drugs experience increased age-matched morbidity and mortality in comparison with those with HIV who do not use drugs.
This CDC report provides updated data related to HIV prevalence among people who inject drugs, documenting findings that underscore the need for low-barrier access to comprehensive and integrated needs-based syringe service programs for necessary prevention and
This PowerPoint slide deck reviews the foundations of harm reduction philosophy and practice, summarizes drug user health issues and trends, and aims to increase cultural competence and humility when working with people who use drugs.
This newly released national strategy confronts the rising rates of opioid and non-opioid related fatal overdoses.
This document describes the critical role that peers have in developing and delivering care for people with HIV and OUD and how a state’s Medicaid program can serve as an essential fiscal resource in supporting peer services.
This discussion guide is intended to elicit a comprehensive and concrete conversation about language, stigma, and discrimination as a means of strengthening care systems and ensuring that people who seek care for HIV and/or substance use disorders, including opioid use disorder, are treated with
This package is a learning tool designed for health departments and community-based organizations newly offering syringe services programs (SSPs) with the purpose of indexing the materials needed for safer injection, what to offer at a syringe services program, and how to explain what materials a
This month’s Connecting Care episode continues the conversation about barriers to methadone treatment for patients, stigma, and what we can learn from other countries to advance policy and practice for methadone in the US.
Pagination
- Previous page ‹‹
- Page 2
- Next page ››